Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivarmacitinib Phase 3 Study in Ulcerative Colitis
NCT05181137Phase 3Recruiting
- Sponsor
- Reistone Biopharma
- Start
- Nov 2021
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 3, randomised, double-blind trial of ivarmacitinib in ulcerative colitis (UC) (5 arms), sponsored by Reistone Biopharma. Primary endpoints: Clinical remission at week 8 (Part 1) and Clinical remission at week 52 (Part 2). Started Nov 2021; status: recruiting.
02
Drugs
ivarmacitinib
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT05181137.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05181137.